Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC)

This is a Phase II, open-label, single-arm, study, designed to evaluate the efficacy and safety of tenalisib in patients with metastatic TNBC, who have received at least one but not more than 3 prior therapies in a metastatic setting.

Trial Details

NCT ID
NCT06189209
Phase
PHASE2
Sponsor
Rhizen Pharmaceuticals SA
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • Tenalisib
Locations (sample)
  • Vijayawada, Andhra Pradesh, India|16.50745,80.6466
  • Bangalore, Karnataka, India|12.97194,77.59369
  • Mumbai, Maharashtra, India|19.07283,72.88261
  • Mumbai, Maharashtra, India|19.07283,72.88261
  • Pune, Maharashtra, India|18.51957,73.85535

Key Eligibility Criteria

  • Patients who have histologically confirmed TNBC.
  • Patients who have received at least 1 but not more than 3 prior chemotherapy regimens in a metastatic setting.
  • Patients with at least one measurable lesion, per RECIST version 1.1 at baseline . Bone-only disease is not permitted.
  • ECOG performance status 0 to 2.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →